Loading stock data…
Abivax SA (ABVX)
$118.95+4.16 (+3.62%)
After Hours$119.20+0.25 (+0.21%)· Last close Sep 8
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ABIVAX Société Anonyme in the Healthcare sector is trading at $118.95 with a market capitalization of $7.2B. Wall Street consensus targets $165.91 (11 analysts), implying a +39.5% move over the next 12 months. The stock is currently 20% below its 52-week high of $148.83, remaining 0.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +39.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$56.23M↑ | -$71.65M↑ | -$80.71M↓ | -$46.50M↑ | -$47.20M |
| Net Income | -$48.47M↑ | -$81.96M↑ | -$153.36M↓ | -$48.41M↑ | -$52.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate inclu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-77.33%
Volume
Today's trading volume
1.60M
Recent News
AbbVie Q2 Earnings Call Highlights
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and Chief Executive Officer Rob Michael said adjusted earnings p
ABIVAX Société Anonyme (ENXTPA:ABVX) Adds Commercial Leaders, Is The Upside Already Priced In?
ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn fresh attention after expanding its commercial leadership team by adding four senior executives across marketing, patient services, sales and commercial operations, and market access for its lead candidate, obefazimod. See our latest analysis for ABIVAX Société Anonyme. Those commercial hires and the recent R&D collaboration with Valerio Therapeutics come after a period where ABIVAX Société Anonyme’s 1 month share price return of 33.49% contrasts...
Abivax (ENXTPA:ABVX) Adds Commercial Leaders And Signs Valerio R And D Deal
Abivax has expanded its Commercial Leadership Team to prepare for potential U.S. commercialization of obefazimod. The company has agreed a binding term sheet for an exclusive worldwide R&D collaboration with Valerio Therapeutics to develop next generation immune mediated inflammatory disease therapies. The moves combine commercial build out with access to RNA technology platforms and new therapeutic candidates. ABIVAX Société Anonyme (ENXTPA:ABVX) is stepping up its U.S. ambitions as it...
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC